Show simple item record

Variation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibition

dc.contributor.authorBrumpton, Ben Michael
dc.contributor.authorFritsche, Lars
dc.contributor.authorZheng, Jie
dc.contributor.authorNielsen, Jonas Bille
dc.contributor.authorMannila, Maria Nastase
dc.contributor.authorSurakka, Ida
dc.contributor.authorRasheed, Humaira
dc.contributor.authorVie, Gunnhild Åberge
dc.contributor.authorGraham, Sarah E.
dc.contributor.authorGabrielsen, Maiken Elvestad
dc.contributor.authorLaugsand, Lars Erik
dc.contributor.authorAukrust, Pål
dc.contributor.authorVatten, Lars Johan
dc.contributor.authorDamås, Jan Kristian
dc.contributor.authorUeland, Thor
dc.contributor.authorJanszky, Imre
dc.contributor.authorZwart, John-Anker
dc.contributor.authorvan't Hooft, Ferdinand M.
dc.contributor.authorSeidah, Nabil Georges
dc.contributor.authorHveem, Kristian
dc.contributor.authorWiller, Cristen
dc.contributor.authorSmith, George Davey
dc.contributor.authorÅsvold, Bjørn Olav
dc.date.accessioned2020-01-31T09:00:33Z
dc.date.available2020-01-31T09:00:33Z
dc.date.issued2019-01-15
dc.description.abstractPCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipoprotein) cholesterol (LDL-C) by increasing uptake in the liver. Although some long-term trials have evaluated their safety, broad investigations of outcomes over the lifetime, leveraging genetic variation in serum PCSK9, have seldomly been conducted. We investigated effects of these variants on a range of outcomes to explore unanticipated effects of long-term PCSK9 inhibition.en_US
dc.identifier.citationBrumpton BM, Fritsche L, Zheng J, Nielsen JB, Mannila MN, Surakka I, Rasheed H, Vie GÅ, Graham SE, Gabrielsen ME, Laugsand LE, Aukrust P, Vatten LJ, Damås JK, Ueland T, Janszky I, Zwart J, van't Hooft, Seidah, Hveem K, Willer C, Smith GD, Åsvold BO. Variation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibition. Circulation. Genomic and precision medicine. 2019;12:e002335(1)en_US
dc.identifier.cristinIDFRIDAID 1694350
dc.identifier.doi10.1161/CIRCGEN.118.002335
dc.identifier.issn2574-8300
dc.identifier.urihttps://hdl.handle.net/10037/17282
dc.language.isoengen_US
dc.publisherAmerican Heart Associationen_US
dc.relation.journalCirculation. Genomic and precision medicine
dc.relation.projectIDinfo:eu-repo/grantAgreement/RCN/BEHANDLING/248817/Norway/National training initiative to make better use of biobanks and health registry data//en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/RCN/BIOTEK2021/299113/Norway/Nordic PerMed: PM-Heart - Precision Diagnostics and Predictions in Ischemic Heart Disease including Identification of Over-Treated Patients//en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/RCN/FRIMEDBIO/ 250335/Norway/The burden of obesity in Norway: morbidity, mortality, health service use and productivity loss//en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holder© 2019 American Heart Association, Inc.en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Gastroenterology: 773en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Gasteroenterologi: 773en_US
dc.titleVariation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibitionen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail
Name:
article.pdf
Size:
888.5Kb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record